Liraglutide's Safety and Tolerability Assessed in Healthy Men in Early-Stage Trial

Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a medication developed for managing type 2 diabetes and obesity. Before widespread clinical use, it is crucial to establish the drug's initial safety, tolerability, and how it behaves in the human body. This Phase 1 study aimed to evaluate the safety, tolerability, pharmacokinetics, and absolute bioavailability of single ascending doses of liraglutide in healthy male volunteers.

The study successfully assessed the safety and tolerability of liraglutide across the five ascending single doses administered. Pharmacokinetic parameters, including the area under the curve (AUC), were measured to understand drug exposure and absorption following both subcutaneous and intravenous administration. The trial concluded that liraglutide was generally well-tolerated within the tested dose range of 1.25 mcg/kg to 20 mcg/kg in healthy male volunteers, with no unexpected safety signals reported that would halt further development. These initial findings provided crucial data on the drug's absorption, distribution, metabolism, and excretion profile, which is essential for determining future dosing strategies. The absolute bioavailability of liraglutide was also determined, providing insights into the fraction of the drug absorbed into the systemic circulation after subcutaneous injection compared to intravenous administration.